A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

ClinicalTrials.gov ID: NCT07137598

Public ClinicalTrials.gov record NCT07137598. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.

Study identification

NCT ID: NCT07137598
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

Afimkibart Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 5, 2025 (Actual)
Primary completion: Apr 17, 2027 (Estimated)
Completion: Oct 2, 2027 (Estimated)
Last update posted: Oct 16, 2026

2025 – 2027

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 18

Facility	City	State	ZIP	Site status
Arizona Arthritis & Rheumatology Associates, P.C.	Avondale	Arizona	85392	Recruiting
SunValley Arthritis Center Ltd.	Peoria	Arizona	85381	Recruiting
University of California Medical Center	La Jolla	California	92037	Recruiting
Cedars Sinai Medical Center	Los Angeles	California	90048	Recruiting
Inland Rheumatology Clinical Trials Incorporated	Upland	California	91786	Recruiting
West Broward Rheumatology Associates, Inc.	Tamarac	Florida	33321	Recruiting
Willow Rheumatology and Wellness PLLC	Willowbrook	Illinois	60527	Recruiting
Equity Medical	Owensboro	Kentucky	42303	Recruiting
Accurate Clinical Research Inc.	Lake Charles	Louisiana	70605	Recruiting
Henry Ford Medical Center- New Center One	Detroit	Michigan	48202	Recruiting
Equity Medical	The Bronx	New York	10455	Recruiting
Ohio State University Wexner Medical Center	Columbus	Ohio	43203	Recruiting
Altoona Center For Clinical Research	Duncansville	Pennsylvania	16635	Recruiting
Precision Comprehensive Clinical Research Solutions	Colleyville	Texas	76034	Recruiting
Accurate Clinical Management	Houston	Texas	77089	Recruiting
DM Clinical Research at Tomball	Tomball	Texas	77375	Recruiting
Tidewater Clinical Research	Chesapeake	Virginia	23320	Recruiting
Rheumatic Disease Center	Glendale	Wisconsin	53217	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07137598, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07137598 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →